Advisors Asset Management Inc. made a new $562,000 investment in Alkerms plc (Nasdaq: ALKS)

Advisors Asset Management Inc. bought a new stake in shares of Alkerms plc (NASDAQ: ALKS – GATE Rating) in the second quarter, HoldingsChannel reports. The institutional investor purchased 18,852 shares of the company’s stock, valued at approximately $562,000.

Other institutional investors have also changed their positions in the company. Steward Partners Investment Advisory LLC increased its stake in shares of Alkerms to 100.0% during the first quarter. Steward Partners Investment Advisory LLC now owns 1,000 shares of the company’s stock valued at $26,000 after purchasing an additional 500 shares during the last quarter. The Trust Company of Vermont acquired a new stake in Alkermes stock valued at approximately $30,000 during the second quarter. Exchange Traded Concepts LLC increased its stake in shares of Alkerms by 132.0% during the second quarter. Exchange Traded Concepts LLC now owns 1,506 shares of the company’s stock valued at $45,000 after purchasing an additional 857 shares during the last quarter. Lazard Asset Management LLC acquired a new stake in shares of Alkermes valued at approximately $72,000 during the first quarter. Finally, Captrust Financial Advisors increased its holding in Alkerms shares by 1,260.9% in the first quarter. Captrust Financial Advisors now owns 6,954 shares of the company’s stock valued at $183,000 after acquiring an additional 6,443 shares in the last quarter. 94.77% of the stock is currently owned by institutional investors and hedge funds.

Wall Street analysts weigh in

Several research analysts recently weighed in on the company. Stifel Nicolaus raised its price objective on Alkerms to $28.00 in a research note on Wednesday, July 27. Mizuho cut its price objective on Alkerms from $36.00 to $34.00 in a research note on Thursday, July 28 and set a “Buy” rating on the stock. Bank of America in a research note on Friday, October 14 raised Alkerms to “Neutral” rating from “Underperform” rating and decreased their price objective for the company from $27.00 to $25.00. Piper Sandler raised Alkerms from a “neutral” rating to an “overweight” rating and raised their price objective for the company from $26.00 to $30.00 in a research note on Thursday, November 3. Finally, StockNews.com downgraded Alkermes from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 2. Three analysts have a hold rating on the company’s stock and five have a buy rating on the company’s stock. The stock has a consensus rating of “Moderate Buy” and a consensus target price of $29.67, according to MarketBeat.com.

alkerms stock performance

Want more great investment ideas?

Shares of the NASDAQ ALKS opened on Friday at $23.44. The company has a quick ratio of 1.89, current ratio of 2.24 and debt-to-equity ratio of 0.28. The 50-day moving average of the business is $22.93 and its 200-day moving average is $26.07. The company has a market cap of $3.85 billion, a P/E ratio of -30.05 and a beta of 0.60. Alkermes plc has a 12 Month Low of $21.24 and a 12 Month High of $32.79.

Alkermes (NASDAQ: ALKS – Get Rating) last issued its quarterly earnings data on Wednesday, November 2. The company reported earnings per share (EPS) of $0.02 for the quarter, missing analysts’ consensus estimates of $0.03 ($0.01). The firm had revenue of $252.36 million for the quarter, compared to the consensus estimate of $271.45 million. Alkerms had a negative net margin of 11.41% and a negative return on equity of 1.10%. The business’s revenue for the quarter was down 14.2% on a year-on-year basis. During the same quarter last year, the firm posted Earnings per Share ($0.02). On average, equity analysts expect Alkerms Plc to post -0.32 EPS for the current year.

Alkerms Profile

(get rating)

Alkermes plc, a biopharmaceutical company, researches, develops and commercialises pharmaceutical products to meet the unmet medical needs of patients in various therapeutic areas in the United States, Ireland and internationally. Its marketed products include Aristada, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcoholism and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; Invega Sustenna for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for the treatment of schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive disease.

Featured Articles

Want to see which other hedge funds are holding ALKS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alkermes plc (NASDAQ: ALKS – Get Rating).

Institutional Ownership by Quarter for Alkerms (NASDAQ:ALKS)

Receive news and ratings for Elker’s Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Alkermes and related companies with MarketBeat.com’s FREE daily email newsletter.

Leave a Comment

Your email address will not be published.

Then We Knew It Was on..” – Roman Reigns Shark Tank Keto Gummies Scam Alert? McDonald’s Halloween Buckets Could Be Back How to Watch Spacecraft Collide With Deep Space Asteroid Grand Theft Auto VI footage leaked after the hack Floyd Mayweather Jr boxer knocks out Mikuru Asakura martial artist